0001213900-25-109409 | 10-Q | XBRL Viewer

Print Document

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	Oct. 31, 2025	Oct. 23, 2025
Subsequent Events [Line Items]
Price per shares of offering (in Dollars per share)		$ 1.9
Aggregate gross proceeds (in Dollars)	$ 7.6	$ 7.6
Common Stock [Member]
Subsequent Events [Line Items]
Shares of common stock	3,100,000	3,100,000
Price per shares of offering (in Dollars per share)	$ 1.9
Common Stock [Member] \| Warrants [Member]
Subsequent Events [Line Items]
Shares of common stock	4,000,000	4,000,000
Common Stock [Member] \| Pre-Funded Warrants [Member]
Subsequent Events [Line Items]
Shares of common stock	935,000	935,000

Stock-Based Compensation

9 Months Ended

Sep. 30, 2025

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

9. STOCK-BASED COMPENSATION

As of September 30, 2025, there were 3,971,778 shares available for the grant of awards under the Company’s 2023 Long Term Incentive Plan (the “2023 Plan”).

Restricted Stock Units

A summary of RSU activities for the nine months ended September 30, 2025 are presented below:

	Number of Shares			Weighted Average Grant Date Fair Value per Share
Nonvested as of January 1, 2025		169,400		$	1.98
Granted		-		$	-
Vested		(109,700	)	$	1.82
Forfeited		-		$	-
Nonvested as of September 30, 2025		59,700		$	1.73

During the nine months ended September 30, 2025, the Company modified the terms of 150,000 outstanding RSU awards with market based and service based vesting conditions to remove all market based vesting conditions and accelerate the service based vesting. The modified award will vest such that 100,000 awards vested upon modification and 50,000 awards will vest on December 31, 2025.

As of September 30, 2025, total unrecognized compensation expense related to restricted stock units was $49 thousand, which is expected to be recognized over a weighted-average period of 0.3 years.

Stock Options

During the nine months ended September 30, 2025, the Company granted stock options to purchase shares of the Company’s common stock to certain employees and board members which vest based on achievement of stock price targets of the Company’s common stock. As of September 30, 2025, options to purchase 550,000 shares of common stock will vest when the 30-day VWAP meets or exceeds $3.00 per share. The grant date fair value of these options were valued using a Monte Carlo valuation model and will be expensed over the requisite service period.

During the nine months ended September 30, 2025, the Company granted 368,706 stock options to purchase shares of the Company’s common stock to certain employees and board members which vest over the continued service period of 1 year.

A summary of stock options activity for the nine months ended September 30, 2025 is presented below:

	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2025		3,594,484		$	2.01		6.0		3,825
Options granted		918,706		$	1.26
Options forfeited		(35,551	)	$	2.85
Options cancelled		(55,368	)	$	3.73
Options exercised		(450,493	)	$	1.44
Outstanding as of September 30, 2025		3,971,778		$	1.87		6.3		2,657
Options vested and exercisable as of September 30, 2025		2,951,221		$	1.98		5.3		1,734

As of September 30, 2025, total unrecognized compensation expense related to stock options was $0.7 million, which is expected to be recognized over a weighted-average period of 1.1 years.

The Company recorded stock-based compensation expense for stock options, RSUs, and restricted stock awards of $0.3 million and $0.9 million for the three and nine months ended September 30, 2025, respectively, and $0.2 million and $0.9 million for the three and nine months ended September 30, 2024, respectively, in general and administrative expenses in the condensed consolidated statements of operations.

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash	$ 10,495	$ 5,157
Accounts receivable, net	990	2,505
Inventory	454	425
Prepaid expenses	706	1,289
Other current assets	818	746
Total current assets	13,463	10,122
Non-current assets:
Property and equipment, net	287	2
Right-of-use assets	1,550	1,971
Total Assets	15,300	12,095
Commitments and contingencies (Note 7)
Current liabilities:
Accounts payable	2,538	4,035
Accrued expenses	2,475	3,210
Deferred revenue	239	960
Lease liabilities, short-term	713	201
Notes payable, current	1,214	422
Notes payable – at fair value		2,365
Warrant liabilities	8,586	6,451
Total current liabilities	15,765	17,644
Notes payable, long-term	6,581
Lease liabilities, long-term	1,157	1,702
Total Liabilities	23,503	19,346
Stockholders’ Deficit
Preferred stock ($0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024
Common stock ($0.0001 par value); 80,000,000 shares authorized; 27,251,034 and 22,594,877 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	3	2
Additional paid-in capital	48,607	40,973
Accumulated other comprehensive income	39	3
Accumulated deficit	(56,852)	(48,229)
Total Stockholders’ Deficit	(8,203)	(7,251)
Total Liabilities and Stockholders’ Deficit	$ 15,300	$ 12,095

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	27,251,034	22,594,877
Common stock, shares outstanding	27,251,034	22,594,877

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2025

Net Loss Per Common Share [Abstract]

Schedule of Computation of Net Loss Per Common Share

The table below summarizes potentially dilutive securities that were excluded from the above computation of net loss per common share as of the periods presented because including them would be anti-dilutive.

	Nine Months Ended September 30,
	2025		2024

Common stock options		3,971,778		3,786,191
Common stock warrants		10,238,460		8,507,311
Unvested restricted stock units		59,700		469,400
Total		14,269,938		12,762,902

Research and Development Revenue - Schedule of Company's Contract Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Contract liabilities:
Balance at beginning	$ 960
Additions	4,303
Reductions	(5,024)
Balance at ending	239
Contract assets:
Balance at beginning
Additions	150
Reductions
Balance at ending	150
Deferred revenue [Member]
Contract liabilities:
Balance at beginning	960
Additions	4,303
Reductions	(5,024)
Balance at ending	239
Unbilled Revenues [Member]
Contract assets:
Balance at beginning
Additions	150
Reductions
Balance at ending	$ 150

Stock-Based Compensation - Schedule of Stock Options Activity (Details) - Equity Option [Member] $ / shares in Units, $ in Thousands		9 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Options, Outstanding \| shares	3,594,484	3,971,778
Weighted Average Exercise Price, Outstanding \| $ / shares	$ 2.01	$ 1.87
Weighted Average Remaining Contractual Life (in years), Outstanding	6 years	6 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding \| $	$ 3,825	$ 2,657
Stock Options vested and exercisable \| shares		2,951,221
Weighted Average Exercise Price, Options vested and exercisable \| $ / shares		$ 1.98
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable		5 years 3 months 18 days
Aggregate Intrinsic Value, Options vested and exercisable \| $		$ 1,734
Stock Options granted \| shares		918,706
Weighted Average Exercise Price, Options granted \| $ / shares		$ 1.26
Stock Options forfeited \| shares		(35,551)
Weighted Average Exercise Price, Options forfeited \| $ / shares		$ 2.85
Stock Options cancelled \| shares		(55,368)
Weighted Average Exercise Price, Options cancelled \| $ / shares		$ 3.73
Stock Options exercised \| shares		(450,493)
Weighted Average Exercise Price, Options exercised \| $ / shares		$ 1.44

Fair Value Measurements

9 Months Ended

Sep. 30, 2025

Fair Value Measurements [Abstract]

FAIR VALUE MEASUREMENTS

3. FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s financial liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024, by level within the fair value hierarchy (in thousands):

	Fair value measured as of September 30, 2025
			Quoted prices		Significant other		Significant
	Fair value at September 30, 2025		in active markets (Level 1)		observable inputs (Level 2)		unobservable inputs (Level 3)
Warrant liabilities	$	8,586	$	5,903	$	-	$	2,683
	$	8,586	$	5,903	$	-	$	2,683

	Fair value measured as of December 31, 2024
			Quoted prices		Significant other		Significant
	Fair value at December 31, 2024		in active markets (Level 1)		observable inputs (Level 2)		unobservable inputs (Level 3)
Warrant liabilities	$	6,451	$	6,410	$	-	$	41
Short-term notes payable – Yorkville	$	2,365	$	-	$	-	$	2,365
	$	8,816	$	6,410	$	-	$	2,406

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2025.

Fair values of cash, accounts receivable, accounts payable, accrued expenses, and short-term debt are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The fair value of the Public Warrants, which trade in active markets, is based on quoted market prices and classified in Level 1 of the fair value hierarchy. The Angel Warrants, Avenue Warrants and Investor Warrants are classified within Level 3 of the fair value hierarchy because their fair values are based on significant inputs that are unobservable in the market.

The fair value of the Angel Warrants at September 30, 2025 was estimated using a Black-Scholes option pricing model. The fair value of the Investor Warrants and Avenue Warrants at March 21, 2025 (issuance date) was estimated using a simulation model.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2025 and 2024 (in thousands):

Balance - January 1, 2024	$	47
Change in fair value		(20	)
Balance - March 31, 2024	$	27
Change in fair value		(11	)
Balance - June 30, 2024	$	16
Change in fair value	$	(12	)
Balance – September 30, 2024	$	4

Balance - January 1, 2025	$	41
Fair value at issuance		2,908
Change in fair value		(37	)
Balance - March 31, 2025	$	2,912
Change in fair value		1,739
Balance - June 30, 2025	$	4,651
Exercise of warrants		(1,705	)
Change in fair value		(264	)
Balance – September 30, 2025		2,682

Both observable and unobservable inputs were used to determine the fair value of warrants that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement:


	September 30, 2025
	Angel Warrants			Investor Warrants			Avenue Warrants			December 31, 2024
Valuation Method	Black Scholes			Monte Carlo			Monte Carlo
Strike price (per share)	$	7.32		$	1.80		$	1.66		$	7.32
Contractual term (years)		1.7			4.0			4.5			2.5
Volatility (annual)		90.8	%		80.0	%		80.0	%		70.6	%
Risk-free rate		3.7	%		3.69	%		3.7	%		4.3	%
Dividend yield (per share)		0.0	%		0.0	%		0.0	%		0.0	%

Warrant Liabilities

On September 11, 2023, in conjunction with the Business Combination, the Company assumed the Public Warrants which had an exercise price of $11.50 per share, are exercisable 30 days after the Business Combination and expire five years after the Business Combination or upon redemption. The Company may redeem the Public Warrants if the Company’s common stock, $0.0001 par value (“Common Stock”) equals or exceeds $18.00 per share for 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of Public Warrants. In November 2024, the Company amended the Public Warrants to have an exercise price of $2.75 per share. As of September 30, 2025, there are 8,433,333 Public Warrants outstanding. Each warrant entitles the registered holder to purchase one share of Common Stock at an exercise price of $2.75 per full share. Pursuant to the Warrant Agreement, a holder of Public Warrants may exercise its Public Warrants only for a whole number of shares of Common Stock. This means that only a whole warrant may be exercised at any given time by a holder of Public Warrants.

In September 2021, the Company issued 73,978 warrants, with a strike price of $7.32 and a five-year life, to SP Angel Corporate Finance LLP (“SP Angel”), who acted as nominated adviser and broker to the Company for the purposes of the AIM Rules relating to the London Stock Market (the “Angel Warrants”). In conjunction with the Business Combination, the Angel Warrants were converted into warrants to purchase Common Stock based on the exchange ratio as set forth in the Business Combination agreements. As of September 30, 2025, there are 73,978 Angel Warrants to purchase Common Stock outstanding.

On March 21, 2025, the Company entered into the purchase agreements with certain stockholders for the sale of an aggregate of 2,068,846 shares of Common Stock, at an offering price of $1.30 per Share (the “Purchase Agreements”). In a concurrent private placement pursuant to the Purchase Agreements (the “Private Placement”), the Company agreed to sell to the investors an aggregate of 2,068,846 warrants to purchase shares of Common Stock at an exercise price of $1.80 per share (the “Investor Warrants”). The Investor Warrants, along with the shares of Common Stock issuable upon the exercise of the Investor Warrants, were offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”). No consideration was received by the Company for the issuance of the Investor Warrants.

As of September 30, 2025, there were 963,077 Investor Warrants to purchase Common Stock outstanding.

The Investor Warrants issued in connection with the Purchase Agreements are exercisable any time on or after March 20, 2025 (the “Issuance Date”) and on or prior to the close of business on the third anniversary of the Issuance Date. Additionally, the Investor Warrants issued in connection with the Purchase Agreements contain adjustment provisions in the event of (i) stock dividends and split, (ii) reclassifications of securities, (iii) issuance of Common Stock or Common Stock Equivalents (as defined in the Purchase Agreements), (iv) pro rata distributions, (v) Fundamental Transactions (as defined in the Warrants), and (vi) subsequent equity sales of shares of common stock or common stock equivalents for a consideration per share less than a price equal to $1.30. The Investor Warrants issued in connection with the Purchase Agreements also include a “Most Favored Nation” clause which grants the holders of such Investor Warrants the right, in their sole discretion, to elect to receive more favorable terms and conditions given to a subsequent investor in a subsequent financing transaction (including, but not limited to, a lower purchase price per share, a higher warrant coverage percentage, a lower warrant exercise price, a longer warrant exercise period, more favorable anti- dilution protections, preferential liquidation rights, enhanced voting rights, reduced fees or commissions, more advantageous registration rights, or the inclusion of additional incentives such as cash bonuses, dividend preferences, or equity sweeteners). The Investor Warrants were determined to be liability classified instruments, as certain terms preclude them from being considered indexed to the Company’s Common Stock. The gross proceeds of the Private Placement and Investor Warrants of $2.7 million were allocated to the Investor Warrants based on their fair value at issuance of $2.2 million, with the residual gross proceeds of $0.5 million allocated to the Common Stock. Total issuance costs incurred of $0.2 million were allocated between the Investor Warrants and Common Stock issued. Issuance costs allocated to the Investor Warrants of $43,000 were expensed during the nine months ended September 30, 2025 as borrowing related costs in the consolidated statement of operations and comprehensive loss. Issuance costs allocated to the Common Stock of $152,000 were recorded in additional paid-in-capital.

In May 2025, 915,000 Investor Warrants, (the “Amended Investor Warrants”) were amended and restated. The amendment extended the contractual term such that the Amended Investor Warrants are exercisable any time on or prior to the close of business on the fifth anniversary of the Issuance Date and resulted in $137,000 increase in the fair value of the warrants.

On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $8.5 million. As part of the Avenue Financing the Company issued 768,072 warrants to Avenue Capital Group which was equal to 8.5% of the total funding commitment (the “Avenue Warrants”). The Avenue Warrants have an exercise price equal to the lower of $1.66 per share and the lowest price per share paid to the Company in cash for common stock through December 31, 2025. The Avenue Warrants were determined to be classified as a liability instrument as certain terms preclude them from being considered indexed to the Company’s Common Stock.

The net proceeds of Avenue Financing of $8.3 million were first allocated to the fair value of the Avenue Warrants, with the residual proceeds being allocated to the debt. The difference between debt proceeds and the amount of those proceeds allocated to debt gave rise to a debt discount of $0.7 million. The discount amount due to the Avenue Warrants of $0.7 million along with the loan fees allocated to the loan of $1.0 million, which includes the final payment of $0.8 million, for an aggregate debt discount and debt issuance costs of $1.7 million, will be amortized as interest expense through maturity using the effective interest method. The portion of loan fees allocated to the Avenue Warrants, of $22,000, were expensed during the nine months ended September 30, 2025 as borrowing related costs in the consolidated statement of operations and comprehensive loss.

As of September 30, 2025, there were 768,072 Avenue Warrants to purchase Common Stock outstanding.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2025

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

On October 23, 2025, the Company entered into a securities purchase agreement which provided for the issuance and sale of 3.1 million shares of common stock, at an offering price of $1.90 per share. In addition, in a concurrent private placement, the Company issued and sold warrants for the purchase of up to 4.0 million shares of common stock and pre-funded warrants to purchase up to 935,000 shares of common stock, for aggregate gross proceeds of $7.6 million.

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2025

Net Loss Per Common Share [Abstract]

NET LOSS PER COMMON SHARE

10. NET LOSS PER COMMON SHARE

	Nine Months Ended September 30,
	2025		2024

Common stock options		3,971,778		3,786,191
Common stock warrants		10,238,460		8,507,311
Unvested restricted stock units		59,700		469,400
Total		14,269,938		12,762,902

Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Mar. 24, 2025	Sep. 30, 2025	Sep. 30, 2024	Sep. 11, 2023
Debt Instrument [Line Items]
Long-term debt, initial draw-down value	$ 8,500
Equity financing, amount raised from institutional investors		$ 2,800
Prime rate plus interest rate	5.25%
Conversion percentage		120.00%
Exercise price (in Dollars per share)				$ 11.5
Net proceeds of avenue financing		$ 8,300
Debt discount		700
Loan fees		700
Amortized as interest expense		1,000
Debt discount		$ 283
Avenue Warrants [Member]
Debt Instrument [Line Items]
Percentage of total funding		8.50%
Exercise price (in Dollars per share)		$ 1.66
Loan fees		$ 22,000
Final payment		800
Debt discount		1,700
Avenue Capital Financing [Member]
Debt Instrument [Line Items]
Interest rate	12.75%
Maturity date	Mar. 01, 2028
Final payment of accrued debt		800
Conversion amount		$ 2,000
Warrant issued (in Shares)		768,072
Convertible Notes [Member]
Debt Instrument [Line Items]
Repayment of convertible notes remaining expense		$ 2,400
Second Tranche [Member]
Debt Instrument [Line Items]
Equity financing, amount raised from institutional investors	$ 6,500
Debt financing agreement, maximum borrowing capacity	$ 7,000
Cash [Member] \| Convertible Notes [Member]
Debt Instrument [Line Items]
Repayment of convertible notes remaining expense		1,200
Common Stock [Member] \| Convertible Notes [Member]
Debt Instrument [Line Items]
Repayment of convertible notes remaining expense		$ 1,200

Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Schedule of Computation of Net Loss Per Common Share [Line Items]
Potentially dilutive securities	14,269,938	12,762,902
Common stock options [Member]
Schedule of Computation of Net Loss Per Common Share [Line Items]
Potentially dilutive securities	3,971,778	3,786,191
Common stock warrants [Member]
Schedule of Computation of Net Loss Per Common Share [Line Items]
Potentially dilutive securities	10,238,460	8,507,311
Unvested restricted stock units [Member]
Schedule of Computation of Net Loss Per Common Share [Line Items]
Potentially dilutive securities	59,700	469,400

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Schedule of Accrued Expenses [Abstract]
Salary and wages	$ 1,757	$ 2,196
Operating expenses	83	355
Benefits	430	411
Non-operating expenses	60	60
Taxes	145	188
Total accrued expenses	$ 2,475	$ 3,210

Fair Value Measurements - Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]
Warrant liabilities	$ 8,586	$ 6,451
Short-term notes payable – Yorkville		2,365
Total	8,586	8,816
Quoted prices in active markets (Level 1) [Member]
Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]
Warrant liabilities	5,903	6,410
Short-term notes payable – Yorkville
Total	5,903	6,410
Significant other observable inputs (Level 2) [Member]
Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]
Warrant liabilities
Short-term notes payable – Yorkville
Total
Significant unobservable inputs (Level 3) [Member]
Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]
Warrant liabilities	2,683	41
Short-term notes payable – Yorkville		2,365
Total	$ 2,683	$ 2,406

- Definition

Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.

+ References + Details

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 158
Sale of common stock net of issuance costs	$ 19

Nature of the Business and Presentation

9 Months Ended

Sep. 30, 2025

Nature of the Business and Presentation [Abstract]

NATURE OF THE BUSINESS AND PRESENTATION

1. NATURE OF THE BUSINESS AND PRESENTATION

Overview

Spectral AI, Inc., a Delaware corporation (the “Company”) is an Artificial Intelligence (“AI”) company focused on predictive medical diagnostics. Our DeepView™ System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characteristics invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound’s capacity to heal or not-heal by a specified time point in the future. Our DeepView System’s output is specifically engineered to assist the physician in making a more accurate, timely and informed decision regarding the treatment of the patient’s wounds. Our focus is on our burn indication.

In February 2024, our DeepView System, comprised of the multispectral imaging (“MSI”) component integrated with the predictive AI-Burn^®software component, received United Kingdom Conformity Assessed (“UKCA”) marking for use in the United Kingdom for burn indications. In June 2025, we filed a De Novo application for the DeepView System with the United States Food and Drug Administration (“FDA”) so that it may achieve Class II medical device designation. Following our anticipated receipt of additional necessary market authorization, our business will have two primary revenue streams, a SaaS (software as a service) offering aligned with SaMD (software as a medical device) regulatory framework, and the imaging device component. The SaaS component will feature a software licensing fee that includes maintenance, image hosting, and access to algorithmic updates. The proprietary imaging device acquires the images for the AI algorithms and is a universal platform to house multiple clinical indications including burn wound healing analysis and other tissue indication assessments. Pricing for these components will be evaluated and strategically set per country and site-of-service for heightened customer adoption.

The DeepView System is comprised of the DeepView-AI Burns^® software and the DeepView SnapShot^® imaging device, and it is intended to be used as an adjunctive tool to aid health care providers in the assessment of burn wound healing potential by differentiating non-healing from healing tissue within an image. The MSI imaging technology within the DeepView SnapShot imaging device consists of patented proprietary multi-spectral optics and sensors, capturing injured tissue images ranging from near ultraviolet light, through the human visible wavelengths, and into the near infrared range. The broad wavelength ranges go beyond what the human eyes can see and capture what medical professionals cannot observe with their naked eyes. This wide range of wavelength images contains wound tissue physiology and captures the viability of various biomarkers within the skin and from the injured tissue spectral signatures. The imaging technology extracts appropriate clinical data and processes the image data to provide the injured tissue spectral signatures to the DeepView AI Burns software AI model and algorithms. The AI algorithm classifies various severities of the injuries as (i) fully damaged (non-healing), (ii) partially damaged or (iii) healthy tissue (healing) and displays a comparison of the original image next to an image with a color overlay of the non-healing portions of the wound. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. Our DeepView System’s proprietary optics can extract millions of pixels of data or AI model features from each group of raw images. This information is then used to advance algorithm optimization, which is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of image data.

The Company has not generated any product revenue to date. The Company currently generates revenue from contract development and research services by providing such services to governmental agencies, primarily to the Biomedical Advanced Research and Development Authority (“BARDA”) and under a contract with the Medical Technology Enterprise Consortium (“MTEC”).

We have received substantial support from the U.S. government for our DeepView System’s application for burn wounds from BARDA, which is part of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response in the United States, established to aid in securing the United States from chemical, biological, radiological, and nuclear threats, as well as from pandemic influenza and emerging infectious diseases. We have also received funding from the National Science Foundation, the National Institute of Health and the Defense Health Agency (“DHA”), an agency within the Department of Defense. On September 27, 2023, the Company executed a new contract with BARDA, providing the Company with additional funding of up to approximately $150.0 million. This includes an initial award of approximately $54.9 million to support the clinical validation study and the distribution of up to 30 DeepView Systems in various emergency rooms and burn centers to support the study. The funding also supported the Company’s FDA De Novo submission of our DeepView AI – Burn software, which was completed on June 30, 2025. The contract also includes options, similar to our prior BARDA contracts, with an additional total value of approximately $95.1 million which can be exercised for additional product development, procurement and the expanded deployment of DeepView Systems at emergency rooms, trauma and burn centers. These deployments will enable the Company to conduct health economic and outcome research studies to support the broader clinical adoption of the DeepView System.

Subject to our receipt of the necessary regulatory market authorizations, we intend to initially sell the DeepView System throughout the United States and the UK for its burn indication. Given our receipt of the UKCA authorization for our burn indication we anticipate initial sales in UK to begin in 2025. The sales channel for our burn indication will be supported by existing and future governmental contracts, primarily from agencies such as BARDA and the DHA. In the United States, there are approximately 100 burn centers, 700 trauma centers and 5,400 federal and community hospitals with emergency rooms where the burn patients are most likely to present upon injury. The DeepView System provides a quick clinical diagnostic decision tool for emergency room clinicians. It can be used to quickly assess the healing potential for burn wounds so decisions regarding whether patients need routine care or should be transferred to trauma centers or burn centers for advanced care and accurate surgical planning can be made in a much more timely fashion. The DeepView System provides an advanced diagnostic assessment of the non-healing areas of a burn in emergency rooms, trauma centers and burn centers. For the DeepView System’s burn application and following receipt of any future contract awards, we plan to partner with the U.S. governmental agency sponsors to implement the distribution of our DeepView System throughout the United States into key regions to support the United States’ mass casualty countermeasure directives, with the goal of making our country better prepared for mass casualty events and saving scarce healthcare resources.

Business Combination

Spectral AI, Inc., a Delaware corporation formerly known as Rosecliff Acquisition Corp I (“Spectral AI” or the “Company”) was formed as a blank check company on November 17, 2020.

On September 11, 2023, the Company consummated a business combination (the “Business Combination”), pursuant to the business combination agreement dated April 11, 2023 (the “Business Combination Agreement”) by and among the Company, Ghost Merger Sub I, a Delaware Corporation, Ghost Merger Sub II, a Delaware corporation and Spectral MD Holdings, Ltd., a Delaware corporation incorporated on March 9, 2009 and headquartered in Dallas, Texas (“Legacy Spectral”). Upon closing of the Business Combination (the “Closing”), the Company changed its name from Rosecliff Acquisition Corp I to Spectral AI, Inc.

In conjunction with the Business Combination, the Company cancelled the redeemable warrants at the Closing that it previously issued to Rosecliff Acquisition Sponsor I LLC, a Delaware limited liability company in connection with the Company’s initial public offering on February 17, 2021, but the 8,433,333 redeemable warrants that were previously issued to the public (the “Public Warrants”) remain outstanding.

Revision of Prior Period Financial Information

During the fourth quarter of 2023, management deferred certain costs associated with a stock offering which was completed during 2024, at which time the costs were recorded as a reduction of additional paid-in capital. Management subsequently determined that these costs should have been expensed during the fourth quarter of 2023. Accordingly, the Company has revised its consolidated statements of changes in stockholders’ equity deficit) as of December 31, 2024, and 2023 to increase both the accumulated deficit and additional paid-in capital by $283,000.

Additionally, during the third quarter of 2023 in conjunction with the accounting for the Business Combination, the Company recognized an income tax receivable asset which should not have been recorded due to uncertainties about collectability. This receivable was written off during the fourth quarter of 2024 through income tax expense. Accordingly, the Company has revised its consolidated statement of changes in stockholders’ deficit to reduce both the accumulated deficit and additional paid-in capital by $157,000 as of December 31, 2024 and to reduce additional paid in capital by $157,000 as of December 31, 2023. The Company has revised its consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 to reduce income tax provision and net loss by $157,000 and to revise the net loss per share accordingly as well.

The net effect of the two corrections described above is a $126,000 increase to both the accumulated deficit and additional paid-in capital as of December 31, 2024, and 2023. The Company has determined that the errors were immaterial to all impacted periods and has corrected the impacted periods as an immaterial correction of an error.

Basis of Presentation

The Company’s condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) or an Accounting Standards Update (“ASU”).

These condensed consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2025, or any other period.

Except as described elsewhere in Note 2 under the heading “Recently accounting pronouncements,” there have been no material changes to the Company’s significant accounting policies as described in the audited consolidated financial statements as of December 31, 2024.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Spectral MD Holdings LLC, Spectral MD Inc., Spectral MD UK Limited (“Spectral MD UK”), Spectral DeepView Limited, and Spectral IP, Inc. (“Spectral IP”) and 1001304798 Ontario, Inc., a newly-formed Canadian company for the purpose of retaining a Canadian employee whom was ultimately not hired. Inter-company transactions and balances have been eliminated in consolidation.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, warrant liabilities, fair value of certain debt, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. Actual results could differ from these estimates.

Segments

Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Chairman of the Board in conjunction with the Company’s executive management team manages the Company’s operations on an aggregate basis for the purpose of allocating resources.

The Company has one operating segment. The accounting policies of the Company’s single operating and reportable segment are the same as those described in the summary of significant accounting policies.

The Company’s method for measuring profitability includes net loss, which the chief operating decision-maker uses to assess performance and make decisions for resource allocation, consistent with the measurement principals for net income(loss) as reported on the Company’s consolidated statement of operations. The significant expenses regularly reviewed by the chief operating decision-maker are consistent with those reported on the Company’s consolidated statement of operations as well as research and development expenses which are disclosed in the footnotes to these financial statements. Certain expenses are reviewed for purposes of assessing operating activities and resource allocation for the Company. The measure of segment assets is reported on the consolidated balance sheets as total assets.

Income Taxes

The Company recorded an income tax provision for Texas Franchise Tax of approximately $2,000 and $54,000 during the three and nine month periods ended September 30, 2025, respectively. The Company recorded an income tax provision of approximately $37,000 and $128,000 for the three and nine month periods ended September 30, 2024, respectively. The effective tax rate was 0.1% and 0.6% for the three and nine month periods ended September 30, 2025, respectively, and 2.5% and 1.7% for the three and nine month periods ended September 30, 2024, respectively.

The tax provision for interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in that quarter. The Company’s effective tax rate differs from the U.S. statutory tax rate in the nine months ended September 30, 2025, primarily due to changes in valuation allowances on deferred tax assets as it is more likely than not that the Company’s deferred tax assets will not be realized.

The Company evaluates its tax positions on a quarterly basis and revises its estimate accordingly.

Concentrations of Credit Risk

Financial instruments which potentially subject the Company to credit risk consist principally of cash and accounts receivable. Primarily all cash is held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash.

Additional credit risk is related to the Company’s concentration of accounts receivable. As of September 30, 2025 and December 31, 2024, accounts receivable were concentrated from one customer (which is a US. government agency) representing 100% and 98% of total net receivables, respectively. No allowance for doubtful accounts were recorded as of September 30, 2025 and December 31, 2024.

One customer (which is a U.S. government agency) accounted for 85% and 92% for the three and nine months ended September 30, 2025, respectively and 90% and 93% for the three and nine months ended September 30, 2024, respectively of the recognized research and development revenue.

Risks and Uncertainties

The Company is subject to a number of risks common to development stage companies in the medical technology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any products that it may develop, development by competitors of technological innovations, compliance with government regulations and the need to obtain additional financing.

Liquidity

As of September 30, 2025 and December 31, 2024, the Company had approximately $10.5 million and $5.2 million, respectively, in cash, and an accumulated deficit of $56.9 million and $48.2 million, respectively. As of September 30, 2025 and December 31, 2024, the Company had approximately $7.8 million and $2.8 million, respectively, of debt outstanding of which $6.6 million and $0 represented long-term debt as of such periods.

On March 24, 2025, the Company completed an equity financing and entered into a long-term debt financing agreement with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (the “Avenue Financing”), which provides for the ability to borrow up to $15.0 million with an initial draw-down of $8.5 million, see Note 6.

In addition to the Avenue Financing, during the nine months ended September 30, 2025, the Company also raised approximately $2.8 million from the issuance of common stock and warrant to institutional investors, as well as existing UK investors, see Note 8.

In October 2025, the Company entered into a securities purchase agreement which provided for the issuance and sale of 3.1 million shares of common stock, at an offering price of $1.90 per share. In addition, in a concurrent private placement the Company issued and sold warrants for the purchase of up to 4.0 million shares of common stock and pre-funded warrants to purchase up to 935,000 shares of common stock, for aggregate gross proceeds of $7.6 million. See Note 12 for further information.

With the PBS BARDA Contract, the MTEC Agreement, and the Avenue Financing, the Company believes it has sufficient working capital to fund operations for at least one year beyond the release date of the condensed consolidated financial statements.

Nature of the Business and Presentation (Details) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2025 USD ($) $ / shares shares	Oct. 23, 2025 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) Segment shares	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 24, 2025 USD ($)	Sep. 27, 2023 USD ($)	Feb. 17, 2021 shares
Nature of the Business and Presentation [Line Items]
Additional fund										$ 150,000
Initial award amount										$ 54,900
Contract additional value			$ 95,100		$ 95,100
Additional paid-in capital			48,607		$ 48,607		$ 40,973
Income tax provision and net loss							157
Increase decrease in accumulated deficit and additional paid-in capital							126	$ 126
Operating segment (in Segment) \| Segment					1
Income tax provision			$ 2	$ 37	$ 54	$ 128
Effective tax rate			0.10%	2.50%	0.60%	1.70%
Allowance for doubtful accounts
Cash			10,500		10,500		5,200
Accumulated deficit			(56,852)		(56,852)		(48,229)
Notes payable			7,800		7,800		2,800
Long-term debt			6,600		6,600		$ 0
Borrowings									$ 15,000
Long-term debt, initial draw-down value									$ 8,500
Equity financing, amount raised from institutional investors			$ 2,800		$ 2,800
Public Warrants [Member]
Nature of the Business and Presentation [Line Items]
Redeemable warrants (in Shares) \| shares			8,433,333		8,433,333						8,433,333
Customer Concentration Risk [Member] \| One Customer [Member] \| Accounts Receivable [Member]
Nature of the Business and Presentation [Line Items]
Concentrations of credit risk percentage					100.00%		98.00%
Customer Concentration Risk [Member] \| One Customer [Member] \| Revenue Benchmark [Member]
Nature of the Business and Presentation [Line Items]
Concentrations of credit risk percentage			85.00%	90.00%	92.00%	93.00%
Subsequent Event [Member]
Nature of the Business and Presentation [Line Items]
Price per share of offering (in Dollars per share) \| $ / shares		$ 1.9
Gross proceeds amount	$ 7,600	$ 7,600
Common Stock [Member] \| Subsequent Event [Member]
Nature of the Business and Presentation [Line Items]
Shares of common stock (in Shares) \| shares	3,100,000	3,100,000
Price per share of offering (in Dollars per share) \| $ / shares	$ 1.9
Common Stock [Member] \| Subsequent Event [Member] \| Warrants [Member]
Nature of the Business and Presentation [Line Items]
Shares of common stock (in Shares) \| shares	4,000,000	4,000,000
Common Stock [Member] \| Subsequent Event [Member] \| Pre-Funded Warrants [Member]
Nature of the Business and Presentation [Line Items]
Shares of common stock (in Shares) \| shares	935,000	935,000
Previously Reported [Member]
Nature of the Business and Presentation [Line Items]
Additional paid-in capital							$ 283	283
Previously Reported [Member] \| Business Combination [Member]
Nature of the Business and Presentation [Line Items]
Additional paid-in capital							$ 157	$ 157

Research and Development Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Sep. 27, 2023
Research and Development Revenue [Line Items]
Awarded amount					$ 54,900
Research and development expense			$ 9,000	$ 14,900
Cost of revenue	$ 2,171	$ 4,506	8,485	12,051
DHA [Member]
Research and Development Revenue [Line Items]
Awarded amount	$ 1,100		1,100
BARDA Contract [Member]
Research and Development Revenue [Line Items]
Research and development expense			8,500	12,000
Cost of revenue			$ 500	$ 2,900

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Stockholders’ Deficit

9 Months Ended

Sep. 30, 2025

Stockholders’ Deficit [Abstract]

STOCKHOLDERS’ DEFICIT

8. STOCKHOLDERS’ DEFICIT

In conjunction with the Closing, the Company’s certificate of incorporation was amended and restated to authorize the issuance of 80,000,000 shares of Common Stock, $0.0001 par value and 1,000,000 shares of preferred stock, $0.0001 par value (the “Preferred Stock”).

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2025

Accrued Expenses [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	September 30,		December 31,
	2025		2024
Salary and wages	$	1,757	$	2,196
Operating expenses		83		355
Benefits		430		411
Non-operating expenses		60		60
Taxes		145		188
Total accrued expenses	$	2,475	$	3,210

Stock-Based Compensation - Schedule of RSU Activities (Details)	9 Months Ended
	Sep. 30, 2025 $ / shares shares
Schedule of RSU Activities [Abstract]
Number of Shares, Nonvested Beginning \| shares	169,400
Weighted Average Grant Date Fair Value per Share, Nonvested Beginning \| $ / shares	$ 1.98
Number of Shares, Granted \| shares
Weighted Average Grant Date Fair Value per Share, Granted \| $ / shares
Number of Shares, Vested \| shares	(109,700)
Weighted Average Grant Date Fair Value per Share, Vested \| $ / shares	$ 1.82
Number of Shares, Forfeited \| shares
Weighted Average Grant Date Fair Value per Share, Forfeited \| $ / shares
Number of Shares, Nonvested Ending \| shares	59,700
Weighted Average Grant Date Fair Value per Share, Nonvested Ending \| $ / shares	$ 1.73

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2025

Notes Payable [Abstract]

Schedule of Convertible Notes, the Related Party Note, and Financing Arrangements

The Company entered into the Avenue Financing, the Yorkville agreement, the Related Party note and financing arrangements for a portion of its Directors and Officers (“D&O”) insurance premiums, as follows (in thousands):

						Principal Repayments				Outstanding Balance
	Amount					Nine Months Ended September 30,				September 30,			December 31,
	Financed		Interest Rate			2025		2024		2025			2024
Avenue Capital Note Principal and Final Payment Fee	$	8,500		Prime + 5.25	%	$	-	$	-	$	9,250		$	-
Yorkville Convertible Notes, at fair value		11,500		0.0	%		2,365		7,129		-			2,365
2024 Insurance Note		596		8.4	%		422		-		-			422
New 2023 Insurance Note		631		8.6	%		-		436		-			-
2023 Insurance Note		151		9.7	%		-		-		-			-
						$	2,787	$	7,565	$	9,250		$	2,787
Less: current portion of notes payable											(1,214	)		(2,787	)
Unamortized debt discounts and debt issuance costs											(1,455	)		-
Notes payable. long term										$	6,581		$	-

Fair Value Measurements (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 24, 2025 USD ($) shares	Mar. 21, 2025 $ / shares shares	Oct. 01, 2024 shares	Sep. 11, 2023 $ / shares	May 31, 2025 USD ($) shares	Mar. 31, 2025 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Dec. 31, 2025 $ / shares	Dec. 31, 2024 $ / shares	Nov. 30, 2024 $ / shares	Sep. 30, 2021 $ / item shares	Feb. 17, 2021 shares
Fair Value Measurements [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares				$ 11.5
Warrants and outstanding term				5 years
Common stock par value (in Dollars per share) \| $ / shares							$ 0.0001			$ 0.0001
Number of trading days				20 days
Number of trading days mature				30 days
Common stock exercise price (in Dollars per share) \| $ / shares							2.75
Warrants to purchase of common stock (in Shares) \| shares												73,978
Strike price (in Dollars per Item) \| $ / item												7.32
Common stock exercise price (in Dollars per share) \| $ / shares		$ 1.8
Common stock consideration price (in Dollars per share) \| $ / shares							$ 1.3
Gross proceed							$ 3,080	$ 2,667
Issuance costs						$ 158
Loan fees							$ 1,000
Public Warrants [Member]
Fair Value Measurements [Line Items]
Common stock par value (in Dollars per share) \| $ / shares				$ 0.0001
Price per share (in Dollars per share) \| $ / shares				$ 18
Warrants to purchase common stock outstanding (in Shares) \| shares							8,433,333						8,433,333
Warrant [Member]
Fair Value Measurements [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares											$ 2.75
Angel Warrants [Member]
Fair Value Measurements [Line Items]
Warrants to purchase common stock outstanding (in Shares) \| shares							73,978
Investor Warrants [Member]
Fair Value Measurements [Line Items]
Warrants to purchase common stock outstanding (in Shares) \| shares					915,000
Issuance of warrants							$ 2,200
Gross proceed							500
Issuance costs							$ 43
Increase the fair value of warrants					$ 137
Avenue Warrants [Member]
Fair Value Measurements [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares							$ 1.66
Warrants to purchase common stock outstanding (in Shares) \| shares							768,072
Warrants to purchase of common stock (in Shares) \| shares	768,072
Initial draw-down amount	$ 8,500
Total funding commitment percentage	8.50%
Net proceeds							$ 8,300
Discount amount							700
Loan fees							22
Final payment							800
Debt issuance costs							$ 1,700
Avenue Warrants [Member] \| Forecast [Member]
Fair Value Measurements [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares									$ 1.66
Investor [Member] \| Warrant [Member]
Fair Value Measurements [Line Items]
Warrants to purchase common stock outstanding (in Shares) \| shares							963,077
Private Placement [Member]
Fair Value Measurements [Line Items]
Aggregate shares (in Shares) \| shares		2,068,846
Issuance of warrants							$ 2,700
Common Stock [Member]
Fair Value Measurements [Line Items]
Aggregate shares (in Shares) \| shares		2,068,846	540,996
Offering price (in Dollars per share) \| $ / shares		$ 1.3
Common Stock [Member] \| Investor Warrants [Member]
Fair Value Measurements [Line Items]
Issuance costs							200
Additional Paid-in Capital [Member]
Fair Value Measurements [Line Items]
Issuance costs							$ 152

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2025
Recent Accounting Pronoucements [Abstract]
Business Combination	*Business Combination* Spectral AI, Inc., a Delaware corporation formerly known as Rosecliff Acquisition Corp I (“Spectral AI” or the “Company”) was formed as a blank check company on November 17, 2020. On September 11, 2023, the Company consummated a business combination (the “Business Combination”), pursuant to the business combination agreement dated April 11, 2023 (the “Business Combination Agreement”) by and among the Company, Ghost Merger Sub I, a Delaware Corporation, Ghost Merger Sub II, a Delaware corporation and Spectral MD Holdings, Ltd., a Delaware corporation incorporated on March 9, 2009 and headquartered in Dallas, Texas (“Legacy Spectral”). Upon closing of the Business Combination (the “Closing”), the Company changed its name from Rosecliff Acquisition Corp I to Spectral AI, Inc. In conjunction with the Business Combination, the Company cancelled the redeemable warrants at the Closing that it previously issued to Rosecliff Acquisition Sponsor I LLC, a Delaware limited liability company in connection with the Company’s initial public offering on February 17, 2021, but the 8,433,333 redeemable warrants that were previously issued to the public (the “Public Warrants”) remain outstanding.
Revision of Prior Period Financial Information	*Revision of Prior Period Financial Information* During the fourth quarter of 2023, management deferred certain costs associated with a stock offering which was completed during 2024, at which time the costs were recorded as a reduction of additional paid-in capital. Management subsequently determined that these costs should have been expensed during the fourth quarter of 2023. Accordingly, the Company has revised its consolidated statements of changes in stockholders’ equity deficit) as of December 31, 2024, and 2023 to increase both the accumulated deficit and additional paid-in capital by $283,000. Additionally, during the third quarter of 2023 in conjunction with the accounting for the Business Combination, the Company recognized an income tax receivable asset which should not have been recorded due to uncertainties about collectability. This receivable was written off during the fourth quarter of 2024 through income tax expense. Accordingly, the Company has revised its consolidated statement of changes in stockholders’ deficit to reduce both the accumulated deficit and additional paid-in capital by $157,000 as of December 31, 2024 and to reduce additional paid in capital by $157,000 as of December 31, 2023. The Company has revised its consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 to reduce income tax provision and net loss by $157,000 and to revise the net loss per share accordingly as well. The net effect of the two corrections described above is a $126,000 increase to both the accumulated deficit and additional paid-in capital as of December 31, 2024, and 2023. The Company has determined that the errors were immaterial to all impacted periods and has corrected the impacted periods as an immaterial correction of an error.
Basis of Presentation	*Basis of Presentation* The Company’s condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) or an Accounting Standards Update (“ASU”). These condensed consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited consolidated financial statements as of that date. The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2025, or any other period. Except as described elsewhere in Note 2 under the heading “Recently accounting pronouncements,” there have been no material changes to the Company’s significant accounting policies as described in the audited consolidated financial statements as of December 31, 2024.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Spectral MD Holdings LLC, Spectral MD Inc., Spectral MD UK Limited (“Spectral MD UK”), Spectral DeepView Limited, and Spectral IP, Inc. (“Spectral IP”) and 1001304798 Ontario, Inc., a newly-formed Canadian company for the purpose of retaining a Canadian employee whom was ultimately not hired. Inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	*Use of Estimates* The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, warrant liabilities, fair value of certain debt, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. Actual results could differ from these estimates.
Segments	*Segments* Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Chairman of the Board in conjunction with the Company’s executive management team manages the Company’s operations on an aggregate basis for the purpose of allocating resources. The Company has one operating segment. The accounting policies of the Company’s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The Company’s method for measuring profitability includes net loss, which the chief operating decision-maker uses to assess performance and make decisions for resource allocation, consistent with the measurement principals for net income(loss) as reported on the Company’s consolidated statement of operations. The significant expenses regularly reviewed by the chief operating decision-maker are consistent with those reported on the Company’s consolidated statement of operations as well as research and development expenses which are disclosed in the footnotes to these financial statements. Certain expenses are reviewed for purposes of assessing operating activities and resource allocation for the Company. The measure of segment assets is reported on the consolidated balance sheets as total assets.
Income Taxes	*Income Taxes* The Company recorded an income tax provision for Texas Franchise Tax of approximately $2,000 and $54,000 during the three and nine month periods ended September 30, 2025, respectively. The Company recorded an income tax provision of approximately $37,000 and $128,000 for the three and nine month periods ended September 30, 2024, respectively. The effective tax rate was 0.1% and 0.6% for the three and nine month periods ended September 30, 2025, respectively, and 2.5% and 1.7% for the three and nine month periods ended September 30, 2024, respectively. The tax provision for interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in that quarter. The Company’s effective tax rate differs from the U.S. statutory tax rate in the nine months ended September 30, 2025, primarily due to changes in valuation allowances on deferred tax assets as it is more likely than not that the Company’s deferred tax assets will not be realized. The Company evaluates its tax positions on a quarterly basis and revises its estimate accordingly.
Concentrations of Credit Risk	*Concentrations of Credit Risk* Financial instruments which potentially subject the Company to credit risk consist principally of cash and accounts receivable. Primarily all cash is held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash. Additional credit risk is related to the Company’s concentration of accounts receivable. As of September 30, 2025 and December 31, 2024, accounts receivable were concentrated from one customer (which is a US. government agency) representing 100% and 98% of total net receivables, respectively. No allowance for doubtful accounts were recorded as of September 30, 2025 and December 31, 2024. One customer (which is a U.S. government agency) accounted for 85% and 92% for the three and nine months ended September 30, 2025, respectively and 90% and 93% for the three and nine months ended September 30, 2024, respectively of the recognized research and development revenue.
Risks and Uncertainties	*Risks and Uncertainties* The Company is subject to a number of risks common to development stage companies in the medical technology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any products that it may develop, development by competitors of technological innovations, compliance with government regulations and the need to obtain additional financing.
Liquidity	*Liquidity* As of September 30, 2025 and December 31, 2024, the Company had approximately $10.5 million and $5.2 million, respectively, in cash, and an accumulated deficit of $56.9 million and $48.2 million, respectively. As of September 30, 2025 and December 31, 2024, the Company had approximately $7.8 million and $2.8 million, respectively, of debt outstanding of which $6.6 million and $0 represented long-term debt as of such periods. On March 24, 2025, the Company completed an equity financing and entered into a long-term debt financing agreement with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (the “Avenue Financing”), which provides for the ability to borrow up to $15.0 million with an initial draw-down of $8.5 million, see Note 6. In addition to the Avenue Financing, during the nine months ended September 30, 2025, the Company also raised approximately $2.8 million from the issuance of common stock and warrant to institutional investors, as well as existing UK investors, see Note 8. In October 2025, the Company entered into a securities purchase agreement which provided for the issuance and sale of 3.1 million shares of common stock, at an offering price of $1.90 per share. In addition, in a concurrent private placement the Company issued and sold warrants for the purchase of up to 4.0 million shares of common stock and pre-funded warrants to purchase up to 935,000 shares of common stock, for aggregate gross proceeds of $7.6 million. See Note 12 for further information. With the PBS BARDA Contract, the MTEC Agreement, and the Avenue Financing, the Company believes it has sufficient working capital to fund operations for at least one year beyond the release date of the condensed consolidated financial statements.

Research and Development Revenue

9 Months Ended

Sep. 30, 2025

Research and Development Revenue [Abstract]

RESEARCH AND DEVELOPMENT REVENUE

4. RESEARCH AND DEVELOPMENT REVENUE

For the three and nine months ended September 30, 2025 and 2024, the Company’s revenues disaggregated by the major sources were as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
BARDA	$	3,442	$	7,567	$	14,472	$	20,734
Other U.S. governmental authorities		350		606		1,092		1,243
Total revenue	$	3,792	$	8,173	$	15,564	$	21,977

The following table presents the activity in the Company’s contract liabilities during the nine months ended September 30, 2025:

	December 31, 2024 Balance		Additions		Reductions			September 30, 2025 Balance
	(in thousands)
Contract liabilities:
Deferred revenue	$	960	$	4,303	$	(5,024	)	$	239
Total contract liabilities	$	960	$	4,303	$	(5,024	)	$	239

The following table presents the activity in the Company’s contract assets during the nine months ended September 30, 2025:

	December 31, 2024 Balance		Additions		Reductions		September 30, 2025 Balance
	(in thousands)
Contract assets:
Unbilled revenue	$	-	$	150	$	-	$	150
Total contract assets	$	-	$	150	$	-	$	150

Research and Development Revenue

We receive funding from a contract by the DHA within the U.S. Department of Defense, which enables us to research and develop a fully portable, handheld version of our DeepView System and has been extended through the second quarter of 2025. We were previously awarded a $1.1 million Sequential Phase II STTR contract by the DHA within the U.S. Department of Defense, which is paid to us monthly, as well as a STTR Phase I and initial Phase II contract from the DHA.

Research and Development Expense

The Company expenses research and development costs as incurred. These expenses include salaries for research and development personnel, consulting fees, product development, pre-clinical studies, clinical trial costs, and other fees and costs related to the development of our technology. For the nine months ended September 30, 2025 and 2024, research and development expense was $9.0 million and $14.9 million, respectively, of which $8.5 million and $12.0 million, respectively, is related to the combined BARDA contract and contracts with other U.S. governmental authorities and included in cost of revenue and $0.5 million and $2.9 million, respectively, is included in general and administrative expenses.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Research and Development Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Research and Development Revenue [Abstract]

Schedule of Revenues Disaggregated

For the three and nine months ended September 30, 2025 and 2024, the Company’s revenues disaggregated by the major sources were as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
BARDA	$	3,442	$	7,567	$	14,472	$	20,734
Other U.S. governmental authorities		350		606		1,092		1,243
Total revenue	$	3,792	$	8,173	$	15,564	$	21,977

Schedule of Company's Contract Liabilities

The following table presents the activity in the Company’s contract liabilities during the nine months ended September 30, 2025:

	December 31, 2024 Balance		Additions		Reductions			September 30, 2025 Balance
	(in thousands)
Contract liabilities:
Deferred revenue	$	960	$	4,303	$	(5,024	)	$	239
Total contract liabilities	$	960	$	4,303	$	(5,024	)	$	239

The following table presents the activity in the Company’s contract assets during the nine months ended September 30, 2025:

	December 31, 2024 Balance		Additions		Reductions		September 30, 2025 Balance
	(in thousands)
Contract assets:
Unbilled revenue	$	-	$	150	$	-	$	150
Total contract assets	$	-	$	150	$	-	$	150

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 31, 2025	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding shares (in Shares)		59,700		59,700		169,400
Unrecognized compensation expense		$ 700		$ 700
Stock-based compensation expense		$ 300	$ 200	$ 900	$ 900
Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vested shares	100,000
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding shares (in Shares)		150,000		150,000
Unrecognized compensation expense		$ 49		$ 49
Recognized over a weighted-average period				3 months 18 days
Restricted Stock Units [Member] \| Forecast [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vested shares	50,000
Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Recognized over a weighted-average period				1 year 1 month 6 days
Purchase of shares (in Shares)				550,000
Exceeds per share (in Dollars per share)		$ 3		$ 3
Granted shares (in Shares)				918,706
Service period				1 year
Common Stock [Member] \| Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted shares (in Shares)				368,706
2023 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Available for grant (in Shares)		3,971,778		3,971,778

Notes Payable

9 Months Ended

Sep. 30, 2025

Notes Payable [Abstract]

NOTES PAYABLE

6. NOTES PAYABLE

						Principal Repayments				Outstanding Balance
	Amount					Nine Months Ended September 30,				September 30,			December 31,
	Financed		Interest Rate			2025		2024		2025			2024
Avenue Capital Note Principal and Final Payment Fee	$	8,500		Prime + 5.25	%	$	-	$	-	$	9,250		$	-
Yorkville Convertible Notes, at fair value		11,500		0.0	%		2,365		7,129		-			2,365
2024 Insurance Note		596		8.4	%		422		-		-			422
New 2023 Insurance Note		631		8.6	%		-		436		-			-
2023 Insurance Note		151		9.7	%		-		-		-			-
						$	2,787	$	7,565	$	9,250		$	2,787
Less: current portion of notes payable											(1,214	)		(2,787	)
Unamortized debt discounts and debt issuance costs											(1,455	)		-
Notes payable. long term										$	6,581		$	-

Avenue Capital Financing

On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $8.5 million.

The term of the Avenue Financing is for three years, with an interest-only payment period of no less than 15 months, which can be extended to 24 months upon achieving the milestones for the second financing tranche. The second financing tranche, which includes an additional $6.5 million in debt financing from Avenue Capital Group is contingent upon; (i) FDA clearance of the DeepView System and (ii) the Company completing a $7.0 million equity raise. The borrowings under the Avenue Financing accrue interest at a variable amount per annum equal to the greater of (i) the sum of (A) the Prime Rate plus (B) 5.25%, and (ii) 12.75%, and they mature on March 1, 2028 (the “Maturity Date”). In addition, on the Maturity Date a final payment of $0.8 million is due to Avenue Capital Group and is accrued as debt as of September 30, 2025.

Up to $2.0 million of the borrowings under the Avenue Financing are convertible at the lender’s option, into a number of shares of common stock at a price per share equal to 120% of the exercise price of the Avenue Warrants discussed below. Pursuant to the guidance in ASC 815-40, Contracts in Entity’s Own Equity, the Company evaluated whether the conversion feature needed to be bifurcated from the host instrument as a freestanding financial instrument. Under ASC 815-40, to qualify for equity classification (or non-bifurcation, if embedded) the instrument (or embedded feature) must be both (1) indexed to the issuer’s own stock and (2) meet the requirements of the equity classification guidance. Based upon the Company’s analysis, it was determined the conversion option is indexed to its own stock and also met all the criteria for equity classification. Accordingly, the conversion option is not required to be bifurcated from the host instrument as a derivative.

As part of the Avenue Financing the Company issued 768,072 warrants to Avenue Capital Group which was equal to 8.5% of the total funding commitment. The Avenue Warrants have an exercise price equal to the lower of $1.66 per share and the lowest price per share paid to the Company in cash for common stock through December 31, 2025. The Avenue Warrants were determined to be classified as a liability instrument as certain terms preclude them from being considered indexed to the Company’s Common Stock.

The net proceeds of Avenue Financing of $8.3 million were first allocated to the fair value of the Avenue Warrants, with the residual proceeds being allocated to the debt. The difference between debt proceeds and the amount of those proceeds allocated to debt gave rise to a debt discount of $0.7 million. The discount amount due to the Avenue Warrants of $0.7 million along with the loan fees allocated to the loan of $1.0 million, which includes the final payment of $0.8 million, for an aggregate debt discount and debt issuance costs of $1.7 million as shown in the table above, will be amortized as interest expense through maturity using the effective interest method. The portion of loan fees allocated to the Avenue Warrants, of $22,000, were expensed during the nine months ended September 30, 2025 as borrowing related costs in the consolidated statement of operations and comprehensive loss.

Repayment of Yorkville Convertible Notes

During the nine months ended September 30, 2025, the Company paid the remaining $2.4 million of Yorkville Convertible Notes of which $1.2 million was settled in cash and $1.2 million was settled in shares of common stock.

Insurance Notes

The Company determined that the carrying amounts of all of the insurance notes approximate fair value due to the short-term nature of borrowings and current market rates of interest.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Stockholders’ Deficit (Details) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Equity [Abstract]
Common stock, shares authorized	80,000,000	80,000,000
Common stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001

Notes Payable - Schedule of Convertible Notes, the Related Party Note, and Financing Arrangements (Details) - Directors and Officers [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Debt Instrument [Line Items]
Principal Repayments	$ 2,787	$ 7,565
Outstanding Balance	9,250		$ 2,787
Less: current portion of notes payable	(1,214)		(2,787)
Unamortized debt discounts and debt issuance costs	(1,455)
Notes payable. long term	6,581
Avenue Capital Note Principal and Final Payment Fee [Member]
Debt Instrument [Line Items]
Amount Financed	$ 8,500
Interest Rate	5.25%
Principal Repayments
Outstanding Balance	9,250
Yorkville Convertible Notes, at fair value [Member]
Debt Instrument [Line Items]
Amount Financed	$ 11,500
Interest Rate	0.00%
Principal Repayments	$ 2,365	7,129
Outstanding Balance			2,365
2024 Insurance Note [Member]
Debt Instrument [Line Items]
Amount Financed	$ 596
Interest Rate	8.40%
Principal Repayments	$ 422
Outstanding Balance			422
New 2023 Insurance Note [Member]
Debt Instrument [Line Items]
Amount Financed	$ 631
Interest Rate	8.60%
Principal Repayments		436
Outstanding Balance
2023 Insurance Note [Member]
Debt Instrument [Line Items]
Amount Financed	$ 151
Interest Rate	9.70%
Principal Repayments
Outstanding Balance

Related Party Transactions (Details) - USD ($) $ in Millions	Mar. 21, 2025	Nov. 04, 2024	Oct. 01, 2024	Mar. 19, 2024	Mar. 07, 2024
Related Party Transactions [Line Items]
Investment from an affiliate (in Dollars)				$ 1.0
Interest rate, percentage					8.00%
Issued shares (in Shares)		1,849,102
Second Anniversary [Member]
Related Party Transactions [Line Items]
Discount rate			5.00%
Spectral IP Note [Member]
Related Party Transactions [Line Items]
Discount rate			5.00%
Maximum [Member] \| Second Anniversary [Member]
Related Party Transactions [Line Items]
Annual interest rate			8.00%
Minimum [Member] \| Second Anniversary [Member]
Related Party Transactions [Line Items]
Annual interest rate			4.00%
Common Stock [Member]
Related Party Transactions [Line Items]
Shares issued (in Shares)	2,068,846		540,996
Issued shares (in Shares)		21,399,851
Preferred Stock [Member]
Related Party Transactions [Line Items]
Issued shares (in Shares)		22,827,380

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (3,552)	$ (7,968)	$ 2,897	$ (1,504)	$ (2,864)	$ (3,205)	$ (8,623)	$ (7,573)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit - USD ($)
$ in Thousands

Common Stock

Additional Paid-in Capital

^[1]

Accumulated Other Comprehensive Income

Accumulated Deficit

^[1]

Total

Balance at Dec. 31, 2023

$ 2

$ 30,908

$ 12

$ (33,071)

$ (2,149)

Balance (in Shares) at Dec. 31, 2023

16,294,935

Stock-based compensation

283

Sale of common stock

2,605

Sale of common stock (in Shares)

1,187,398

Cumulative translation adjustment

(2)

Net income (loss)

(3,205)

Balance at Mar. 31, 2024

$ 2

33,796

(36,276)

(2,468)

Balance (in Shares) at Mar. 31, 2024

17,482,333

Balance at Dec. 31, 2023

$ 2

30,908

(33,071)

(2,149)

Balance (in Shares) at Dec. 31, 2023

16,294,935

Net income (loss)

(7,573)

Balance at Sep. 30, 2024

$ 2

35,841

(40,644)

(4,776)

Balance (in Shares) at Sep. 30, 2024

18,513,073

Balance at Mar. 31, 2024

$ 2

33,796

(36,276)

(2,468)

Balance (in Shares) at Mar. 31, 2024

17,482,333

Stock-based compensation

402

Issuance of common stock under the SEPA

225

Issuance of common stock under the SEPA (in Shares)

94,937

Vesting of restricted stock units

Vesting of restricted stock units (in Shares)

29,097

Cumulative translation adjustment

Net income (loss)

(2,864)

Balance at Jun. 30, 2024

$ 2

34,423

(39,140)

(4,705)

Balance (in Shares) at Jun. 30, 2024

17,606,367

Stock-based compensation

173

Issuance of common stock under the SEPA

1,245

Issuance of common stock under the SEPA (in Shares)

906,706

Cumulative translation adjustment

Net income (loss)

(1,504)

Balance at Sep. 30, 2024

$ 2

35,841

(40,644)

(4,776)

Balance (in Shares) at Sep. 30, 2024

18,513,073

Balance at Dec. 31, 2024

$ 2

40,973

(48,229)

(7,251)

Balance (in Shares) at Dec. 31, 2024

22,594,877

Stock-based compensation

200

Issuance of common stock from debt offering

377

Issuance of common stock from debt offering (in Shares)

2,028,846

Issuance of common stock to pay convertible debt

1,433

Issuance of common stock to pay convertible debt (in Shares)

610,426

Sale of common stock

543

Sale of common stock (in Shares)

310,925

Exercise of stock options

158

Exercise of stock options (in Shares)

43,047

Cumulative translation adjustment

Net income (loss)

2,897

Balance at Mar. 31, 2025

$ 2

43,684

(45,332)

(1,626)

Balance (in Shares) at Mar. 31, 2025

25,588,121

Balance at Dec. 31, 2024

$ 2

40,973

(48,229)

(7,251)

Balance (in Shares) at Dec. 31, 2024

22,594,877

Net income (loss)

(8,623)

Balance at Sep. 30, 2025

$ 3

48,607

(56,852)

(8,203)

Balance (in Shares) at Sep. 30, 2025

27,251,034

Balance at Mar. 31, 2025

$ 2

43,684

(45,332)

(1,626)

Balance (in Shares) at Mar. 31, 2025

25,588,121

Stock-based compensation

411

Vesting of restricted stock units

Vesting of restricted stock units (in Shares)

109,698

Issuance of common stock from debt offering

Issuance of common stock from debt offering (in Shares)

40,000

Cumulative translation adjustment

Net income (loss)

(7,968)

Balance at Jun. 30, 2025

$ 2

44,095

(53,300)

(9,151)

Balance (in Shares) at Jun. 30, 2025

25,737,819

Stock-based compensation

261

Exercise of warrants

$ 1

3,696

3,697

Exercise of warrants (in Shares)

1,105,769

Exercise of stock options

555

Exercise of stock options (in Shares)

407,446

Cumulative translation adjustment

(13)

Net income (loss)

(3,552)

Balance at Sep. 30, 2025

$ 3

$ 48,607

$ 39

$ (56,852)

$ (8,203)

Balance (in Shares) at Sep. 30, 2025

27,251,034

[1]	Reflects an adjustment of $126,000 as compared to previously reported amounts as of December 31, 2024. Reflects an adjustment of $(157,000) in Additional Paid in Capital and $(283,000) in Accumulated Deficit as of December 31, 2023. See further discussion in Note 1.

Fair Value Measurements - Schedule of Changes in Level 3 Warrant Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Schedule of Changes in Level 3 Warrant Liabilities Measured at Fair Value [Abstract]
Balance beginning	$ 4,651	$ 2,912	$ 41	$ 16	$ 27	$ 47	$ 41	$ 47
Fair value at issuance			2,908
Exercise of warrants	(1,705)						(1,992)
Change in fair value	(264)	1,739	(37)	(12)	(11)	(20)
Balance ending	$ 2,682	$ 4,651	$ 2,912	$ 4	$ 16	$ 27	$ 2,682	$ 4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (8,623)	$ (7,573)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	42	6
Amortization of debt issuance costs	283
Stock-based compensation	872	858
Amortization of right-of-use assets	421	448
Change in fair value of warrant liabilities	932	(718)
Change in fair value of notes payable	(220)	7
Cost from issuance of common stock		372
Issuances of shares for borrowing related costs	241	280
Changes in operating assets and liabilities:
Accounts receivable	1,515	(488)
Inventory	(29)	(213)
Prepaid expenses	583	542
Other assets	(72)	(208)
Accounts payable	(1,497)	188
Accrued expenses	(735)	(1,047)
Deferred revenue	(721)	(1,580)
Lease liabilities	(360)	(542)
Net cash used in operating activities	(7,368)	(9,668)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs	3,080	2,667
Proceeds from notes payable, net of borrowing costs	8,260	11,500
Proceeds from notes payable - related party		1,000
Payments for notes payable	(1,375)	(6,600)
Proceeds from warrant exercises	1,992
Stock option exercises	713
Net cash provided by financing activities	12,670	8,567
Effect of exchange rate changes on cash	36	13
Net increase/(decrease) in cash	5,338	(1,088)
Cash, beginning of period	5,157	4,790
Cash, end of period	10,495	3,702
Supplemental cash flow information:
Cash paid for interest	12
Cash paid for taxes	1	20
Noncash investing and financing activities disclosure:
Tenant improvement allowance payments made by the lessor directly to a third party	(327)
Recognition of Right-of-use assets and related lease liabilities upon lease amendment		1,771
Prepaid asset acquired, net of cancellation, for debt and accounts payable		596
Issuance of common stock to settle notes payable	$ 1,192	$ 1,245

Related Party Transactions

9 Months Ended

Sep. 30, 2025

RELATED PARTY TRANSACTIONS

11. RELATED PARTY TRANSACTIONS

On March 7, 2024, the Company formed a new wholly-owned subsidiary, Spectral IP, to be utilized to acquire artificial intelligent intellectual property with a specific emphasis on healthcare. On March 19, 2024, the Company announced that Spectral IP received a $1.0 million investment from an affiliate of its largest stockholder for the development of its artificial intelligence intellectual property portfolio. The investment was structured as a note payable with a one-year maturity, an interest rate of 8%, and requiring earlier prepayment if the Company spins off Spectral IP to the Company’s stockholders or if Spectral IP is sold to a third party (the “Spectral IP Note”).

On October 1, 2024, the Spectral IP Note was amended to (i) reduce the annual interest rate from 8% to 4%, (ii) extend the term of the Spectral IP Note through the second anniversary of the issuance date, March 18, 2026, (iii) include a conversion feature at the option of either the holder or Spectral IP to convert the then outstanding principal and accrued but unpaid interest into shares of the Company at any time (into such number of shares calculated by taking a five percent (5.00%) discount to the closing price of the Common Stock on the day prior to the date of notice to the Company of the exercise of the conversion right) and at maturity, respectively, and (iv) provide for registration rights of any shares of the Company issued in satisfaction of the outstanding obligations. The holder of the Spectral IP Note exercised a number of conversion rights throughout the fourth quarter of 2024 for the full conversion of the Spectral IP Note in exchange for a total of 540,996 shares of the Common Stock, which represents a 5.00% discount to the closing price of the Company’s shares of Common Stock on the day prior to the date of notice of the holder’s exercise of its conversion right. There were no outstanding obligations due and owing under the Spectral IP Note as of September 30, 2025.

On May 5, 2025, the Company entered into an intellectual property license agreement pursuant to which Spectral IP received a worldwide, non-exclusive, license to one international patent asset of the Company for the purposes of commercializing and monetizing outside the core areas of focus of the Company on market terms and conditions that are to be finalized.

Spectral IP Reorganization

On November 4, 2024, Spectral IP entered into a purchase agreement with Sauvegarder Investment Management, Inc. (“Sauvegarder IM”, formerly known as SIM Tech Inc.), Sauvegarder IM was formed on March 25, 2024 with a focus on IP-related transactions. Pursuant to the purchase agreement, as amended, Spectral IP will acquire all of the outstanding common stock of Sauvegarder IM in exchange for issuing to the Sauvegarder IM stockholders 21,399,851 shares of common stock of Spectral IP and 22,827,380 shares of preferred stock of Spectral IP. Additionally, the Company has agreed to forfeit all shares of Spectral IP it holds other than 1,849,102, which is the value the parties attribute to the intellectual property license agreement held by Spectral IP.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Recent Accounting Pronoucements

9 Months Ended

Sep. 30, 2025

Recent Accounting Pronoucements [Abstract]

RECENT ACCOUNTING PRONOUCEMENTS

2. RECENT ACCOUNTING PRONOUCEMENTS

Recently Issued Accounting Standards

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires more detailed income tax disclosures, requiring entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. This update will be effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40), requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The disclosures required under the guidance can be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements and disclosures.

Research and Development Revenue - Schedule of Revenues Disaggregated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Schedule of Revenues Disaggregated [Line Items]
Total revenue	$ 3,792	$ 8,173	$ 15,564	$ 21,977
BARDA [Member]
Schedule of Revenues Disaggregated [Line Items]
Total revenue	3,442	7,567	14,472	20,734
Other U.S. governmental authorities [Member]
Schedule of Revenues Disaggregated [Line Items]
Total revenue	$ 350	$ 606	$ 1,092	$ 1,243

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Research and development revenue	$ 3,792	$ 8,173	$ 15,564	$ 21,977
Cost of revenue	(2,171)	(4,506)	(8,485)	(12,051)
Gross profit	1,621	3,667	7,079	9,926
Operating costs and expenses:
General and administrative	4,962	4,553	13,439	15,397
Total operating costs and expenses	4,962	4,553	13,439	15,397
Operating loss	(3,341)	(886)	(6,360)	(5,471)
Other income (expense):
Net interest expense	(300)	(8)	(597)
Borrowing related costs	(164)	(1,059)	(869)	(2,034)
Change in fair value of warrant liability	264	350	(932)	718
Change in fair value of notes payable		94	220	(7)
Foreign exchange transaction loss, net	(9)	(9)	(31)	(34)
Other income (expenses), including transactions costs		51		(617)
Total other income (expense), net	(209)	(581)	(2,209)	(1,974)
Loss before income taxes	(3,550)	(1,467)	(8,569)	(7,445)
Income tax provision	(2)	(37)	(54)	(128)
Net loss	$ (3,552)	$ (1,504)	$ (8,623)	$ (7,573)
Net loss per share of common stock
Basic (in Dollars per share)	$ (0.13)	$ (0.08)	$ (0.34)	$ (0.44)
Diluted (in Dollars per share)	$ (0.13)	$ (0.08)	$ (0.34)	$ (0.44)
Weighted average common shares outstanding
Basic (in Shares)	26,318,624	17,862,240	25,147,179	17,342,203
Diluted (in Shares)	26,318,624	17,862,240	25,147,179	17,342,203
Other comprehensive loss:
Foreign currency translation adjustments	$ (13)	$ 15	$ 36	$ 13
Total comprehensive loss	$ (3,565)	$ (1,489)	$ (8,587)	$ (7,560)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2025

Fair Value Measurements [Abstract]

Schedule of Financial Liabilities that are Measured at Fair Value on a Recurring Basis

	Fair value measured as of September 30, 2025
			Quoted prices		Significant other		Significant
	Fair value at September 30, 2025		in active markets (Level 1)		observable inputs (Level 2)		unobservable inputs (Level 3)
Warrant liabilities	$	8,586	$	5,903	$	-	$	2,683
	$	8,586	$	5,903	$	-	$	2,683

	Fair value measured as of December 31, 2024
			Quoted prices		Significant other		Significant
	Fair value at December 31, 2024		in active markets (Level 1)		observable inputs (Level 2)		unobservable inputs (Level 3)
Warrant liabilities	$	6,451	$	6,410	$	-	$	41
Short-term notes payable – Yorkville	$	2,365	$	-	$	-	$	2,365
	$	8,816	$	6,410	$	-	$	2,406

Schedule of Changes in Level 3 Warrant Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2025 and 2024 (in thousands):

Balance - January 1, 2024	$	47
Change in fair value		(20	)
Balance - March 31, 2024	$	27
Change in fair value		(11	)
Balance - June 30, 2024	$	16
Change in fair value	$	(12	)
Balance – September 30, 2024	$	4

Balance - January 1, 2025	$	41
Fair value at issuance		2,908
Change in fair value		(37	)
Balance - March 31, 2025	$	2,912
Change in fair value		1,739
Balance - June 30, 2025	$	4,651
Exercise of warrants		(1,705	)
Change in fair value		(264	)
Balance – September 30, 2025		2,682

Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement:


	September 30, 2025
	Angel Warrants			Investor Warrants			Avenue Warrants			December 31, 2024
Valuation Method	Black Scholes			Monte Carlo			Monte Carlo
Strike price (per share)	$	7.32		$	1.80		$	1.66		$	7.32
Contractual term (years)		1.7			4.0			4.5			2.5
Volatility (annual)		90.8	%		80.0	%		80.0	%		70.6	%
Risk-free rate		3.7	%		3.69	%		3.7	%		4.3	%
Dividend yield (per share)		0.0	%		0.0	%		0.0	%		0.0	%

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2025	Nov. 11, 2025
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	SPECTRAL AI, INC.
Entity Central Index Key	0001833498
Entity File Number	001-40058
Entity Tax Identification Number	85-3987148
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	2515 McKinney Avenue
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75201
Entity Phone Fax Numbers [Line Items]
City Area Code	(972)
Local Phone Number	499-4934
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		30,688,895
Common stock, par value $0.0001 per share
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	MDAI
Security Exchange Name	NASDAQ
Redeemable warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $2.75
Entity Listings [Line Items]
Title of 12(b) Security	Redeemable warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $2.75
Trading Symbol	MDAIW
Security Exchange Name	NASDAQ

Accrued Expenses

9 Months Ended

Sep. 30, 2025

Accrued Expenses [Abstract]

ACCRUED EXPENSES

5. ACCRUED EXPENSES

Accrued expenses consist of the following as of September 30, 2025 and December 31, 2024 (in thousands):

	September 30,		December 31,
	2025		2024
Salary and wages	$	1,757	$	2,196
Operating expenses		83		355
Benefits		430		411
Non-operating expenses		60		60
Taxes		145		188
Total accrued expenses	$	2,475	$	3,210

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2025

Stock-Based Compensation [Abstract]

Schedule of RSU Activities

A summary of RSU activities for the nine months ended September 30, 2025 are presented below:

	Number of Shares			Weighted Average Grant Date Fair Value per Share
Nonvested as of January 1, 2025		169,400		$	1.98
Granted		-		$	-
Vested		(109,700	)	$	1.82
Forfeited		-		$	-
Nonvested as of September 30, 2025		59,700		$	1.73

Schedule of Stock Options Activity

A summary of stock options activity for the nine months ended September 30, 2025 is presented below:

	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2025		3,594,484		$	2.01		6.0		3,825
Options granted		918,706		$	1.26
Options forfeited		(35,551	)	$	2.85
Options cancelled		(55,368	)	$	3.73
Options exercised		(450,493	)	$	1.44
Outstanding as of September 30, 2025		3,971,778		$	1.87		6.3		2,657
Options vested and exercisable as of September 30, 2025		2,951,221		$	1.98		5.3		1,734

Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

7. COMMITMENTS AND CONTINGENCIES

Legal Matters

The Company is not a party to any material legal proceedings or pending claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities, none of which we believe are material or would be expected to have, individually or in the aggregate, a material adverse effect on our business, financial condition, cash flows or results of operations.

Fair Value Measurements - Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement (Details)	Sep. 30, 2025	Dec. 31, 2024
Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Valuation Method	Black Scholes
Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Valuation Method	Monte Carlo
Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Valuation Method	Monte Carlo
Strike price (per share) [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs		7.32
Strike price (per share) [Member] \| Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	7.32
Strike price (per share) [Member] \| Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	1.8
Strike price (per share) [Member] \| Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	1.66
Contractual term (years) [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs		2.5
Contractual term (years) [Member] \| Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	1.7
Contractual term (years) [Member] \| Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	4
Contractual term (years) [Member] \| Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	4.5
Volatility (annual) [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs		70.6
Volatility (annual) [Member] \| Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	90.8
Volatility (annual) [Member] \| Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	80
Volatility (annual) [Member] \| Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	80
Risk-free rate [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs		4.3
Risk-free rate [Member] \| Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	3.7
Risk-free rate [Member] \| Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	3.69
Risk-free rate [Member] \| Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	3.7
Dividend yield (per share) [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs		0
Dividend yield (per share) [Member] \| Angel Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	0
Dividend yield (per share) [Member] \| Minimum [Member] \| Investor Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	0
Dividend yield (per share) [Member] \| Minimum [Member] \| Avenue Warrants [Member]
Schedule of Quantitative Information Regarding Level 3 Warrant Liability Fair Value Measurements Inputs at Their Measurement [Line Items]
Warrant liability fair value measurements inputs	0